-
Cancer Research UK, Biotech Partner on Drug Discovery
Forma Therapeutics in Watertown, Massachusetts and Cancer Research Technology Ltd. in London are collaborating on finding drug candidates that target the regulators of protein levels in cells, a key factor in a number of diseases, including cancer. Cancer Research Technology is the for-profit commercialization subsidiary of the foundation Cancer Research UK. Financial amounts to be…
-
Electronic Skin Material Devised to Detect Multiple Senses
Chemical engineers at Technion-Israel Institute of Technology developed a flexible sensor that can simultaneously detect touch, humidity, and temperature. The team led by Technion’s Hossam Haick published its findings in the June issue of the journal ACS Applied Materials & Interfaces (paid subscription required). The Technion team aimed to develop a flexible electronic sensor that would…
-
Lighter, Stronger Metallic Bubble Wrap Developed
Engineers at North Carolina State University in Raleigh created a flexible metal foam material that’s lighter and stronger than sheet metal, but more heat and chemical resistant than plastic bubble wraps. The team of Advanced Materials Research Lab director Afsaneh Rabiei and doctoral candidate Di Miao presented their findings on 24 June at the Conference…
-
First Birth Reported for Full-Genome Screened IVF Embryo
A British woman gave birth to a boy in June, following a full genomic sequencing of the embryo to identify potential genetic disorders. Researchers at University of Oxford in the U.K., with colleagues from the reproductive genetics company Reprogenetics in New Jersey and fertility centers in the U.S., described their results today in London at…
-
FDA Approves Maintenance Drug to Treat Opioid Dependence
Orexo AB, a pharmaceutical company in Uppsala, Sweden says it received approval from the U.S. Food and Drug Administration to market in the U.S. its drug Zubsolv for the treatment of opioid dependence, such as from prescription pain killers. FDA, says the company, approved the drug as a maintenance treatment — a substitute for addictive…
-
Early Trial Results Show Venous Leg Ulcer Drug Efficacy
The biotechnology company Pergamum AB in Solna, Sweden reports an early-stage clinical trial shows its drug to treat venous leg ulcers improved healing among patients taking the drug compared to a placebo. The trial also showed the drug, code-named LL-37, was well-tolerated at lower doses. Venous leg ulcers are shallow wounds appearing on the skin…
-
Going Fourth
It’s Independence Day in the U.S., so Science Business will take a holiday today. We’ll be back tomorrow. For those in the U.S., enjoy your holiday. * * *
-
Biotech, Cancer Center Partner on Tumor-Targeting Peptides
Blaze Bioscience, a biotechnology company in Seattle, is partnering with the Fred Hutchinson Cancer Research Center, also in Seattle, to develop and commercialize drug candidates based on engineered peptides that better target tumor cells than conventional cancer drugs. Financial amounts in the agreement were not disclosed. The Hutchinson Center is conducting research on optides —…
-
FDA Giving Roche Leukemia Antibody Priority Review
An engineered antibody to treat chronic lymphocytic leukemia developed by the pharmaceutical company Roche is receiving priority review from the U.S. Food and Drug Administration, which sets a goal of six months to complete its evaluation. The therapy is obinutuzumab, code-named GA101, which in May, FDA designated as a “breakthrough” that expedites the review process…
-
University, 23andMe Identify Genetic Allergy Associations
Two large-scale population studies associating allergies to genomics discovered 16 genetic regions associated with common allergies, including pollen, cats, and dust mites. The findings from the studies that combined databases collected by the Avon Longitudinal Study of Parents and Children at Bristol University in the U.K. and the personal genetics company 23andMe in Mountain View,…